What Nuvation Bio Inc. does.

On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (“Merger Agreement”).

Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”). On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).

In connection with the closing of the Merger, our Class A common stock and warrants to purchase shares of our Class A common stock began trading on The New York Stock Exchange under the symbols “NUVB” and “NUVB.WS,” respectively, on February 11, 2021. The disclosure in Items 1 and 1A of this report gives effect to the Merger and includes the operations of Legacy Nuvation Bio prior to the Merger.

Revenue and profit, by fiscal year.

More on NUVB.

• Nuvation Bio Inc. summary
• Nuvation Bio Inc. financial statements
• Nuvation Bio Inc. key metrics
• Nuvation Bio Inc. health scores and style box
• Nuvation Bio Inc. earnings
• Nuvation Bio Inc. dividends
• Nuvation Bio Inc. valuation
• Nuvation Bio Inc. ownership and insiders
• Nuvation Bio Inc. peers

Figures from Nuvation Bio Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.